Immunovant
IMVT
118 hedge funds and large institutions have $322M invested in Immunovant in 2021 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 40 increasing their positions, 45 reducing their positions, and 20 closing their positions.
1,952% more call options, than puts
Call options by funds: $22.9M | Put options by funds: $1.12M
10% more capital invested
Capital invested by funds: $293M → $322M (+$28.1M)
3.53% more ownership
Funds ownership: 29.38% → 32.91% (+3.5%)
5% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 20
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1% less funds holding
Funds holding: 119 → 118 (-1)
11% less repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 45
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$7.43M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
+$4.73M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$4.02M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$2.18M |
| 5 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
+$1.96M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$11M |
| 2 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$3.65M |
| 3 |
Morgan Stanley
New York
|
-$3.04M |
| 4 |
Two Sigma Investments
New York
|
-$2.4M |
| 5 |
Two Sigma Advisers
New York
|
-$2.28M |
IMVT Hedge Fund Activity: Q4 2021 in Review
118 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Immunovant (IMVT) for Q4 2021, worth a combined $322M — up 9.6% from $293M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new IMVT positions and 20 closed out — a net gain of 1 holder — while 40 added to existing stakes and 45 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $7.43M. The largest seller was State Street, cutting an estimated $11M.
- 118 institutional investors held Immunovant (IMVT) as of Q4 2021, down from 119 in Q3 2021.
- Funds reported $322M of Immunovant stock for Q4 2021, up 9.6% quarter-over-quarter.
- 21 funds opened new Immunovant positions in Q4 2021 and 20 closed out, a net change of +1 holder.
- The largest Immunovant buyer in Q4 2021 was Point72 Asset Management, an estimated $7.43M added.
- The largest Immunovant seller in Q4 2021 was State Street, an estimated $11M sold.
Based on aggregated 13F filings for Q4 2021.